CHEBI:68478 - everolimus

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name everolimus
ChEBI ID CHEBI:68478
Definition A macrocyclic lactone that is rapamycin in which the hydroxy group attached to the cyclohexyl moiety has been converted into the corresponding 2-hydroxyethyl ether. It is an immunosuppressant and antineoplastic agent.
Stars This entity has been manually annotated by the ChEBI Team.
Supplier Information
Download Molfile XML SDF
Wikipedia License
Waiting for wikipedia content
Read full article at Wikipedia
Formula C53H83NO14
Net Charge 0
Average Mass 958.22440
Monoisotopic Mass 957.58136
InChI InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
InChIKey HKVAMNSJSFKALM-GKUWKFKPSA-N
SMILES [H][C@]1(CC[C@@H](OCCO)[C@@H](C1)OC)C[C@@H](C)[C@]1([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]2([H])CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@@]2([H])C(=O)O1)OC
Roles Classification
Biological Role(s): immunosuppressive agent
An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response.
mTOR inhibitor
A protein kinase inhibitor of the mammalian target of rapamycin (mTOR), a protein that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis and transcription. mTOR inhibitors are used to prevent transplant rejection and in treatment of cancer.
anticoronaviral agent
Any antiviral agent which inhibits the activity of coronaviruses.
Application(s): immunosuppressive agent
An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response.
geroprotector
Any compound that supports healthy aging, slows the biological aging process, or extends lifespan.
antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
View more via ChEBI Ontology
ChEBI Ontology
Outgoing everolimus (CHEBI:68478) has functional parent sirolimus (CHEBI:9168)
everolimus (CHEBI:68478) has role anticoronaviral agent (CHEBI:149553)
everolimus (CHEBI:68478) has role antineoplastic agent (CHEBI:35610)
everolimus (CHEBI:68478) has role geroprotector (CHEBI:176497)
everolimus (CHEBI:68478) has role immunosuppressive agent (CHEBI:35705)
everolimus (CHEBI:68478) has role mTOR inhibitor (CHEBI:68481)
everolimus (CHEBI:68478) is a cyclic acetal (CHEBI:59770)
everolimus (CHEBI:68478) is a cyclic ketone (CHEBI:3992)
everolimus (CHEBI:68478) is a ether (CHEBI:25698)
everolimus (CHEBI:68478) is a macrolide lactam (CHEBI:145565)
everolimus (CHEBI:68478) is a primary alcohol (CHEBI:15734)
everolimus (CHEBI:68478) is a secondary alcohol (CHEBI:35681)
IUPAC Name
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
INNs Sources
évérolimus WHO MedNet
everolimus WHO MedNet
everolimus WHO MedNet
everolimusum WHO MedNet
Synonyms Sources
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,35R)-1,18-dihydroxy-12-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone IUPAC
40-O-(2-hydroxyethyl)-rapamycin ChemIDplus
42-O-(2-hydroxyethyl)rapamycin ChemIDplus
Everolimus ChemIDplus
RAD 001 ChemIDplus
RAD001 ChemIDplus
SDZ RAD ChemIDplus
SDZ-RAD ChemIDplus
Brand Names Sources
Afinitor ChemIDplus
Afinitor Disperz ChemIDplus
Certican ChemIDplus
Votubia DrugCentral
Xience V ChemIDplus
Zortress ChemIDplus
Manual Xrefs Databases
1118 DrugCentral
21106307 ChemSpider
CN102138903 Patent
D02714 KEGG DRUG
DB01590 DrugBank
Everolimus Wikipedia
HMDB0015529 HMDB
LSM-43172 LINCS
RU2008143550 Patent
WO2012066502 Patent
View more database links
Registry Number Type Source
159351-69-6 CAS Registry Number ChemIDplus
Citations Waiting for Citations Types Sources
22363408 PubMed citation Europe PMC
22404500 PubMed citation Europe PMC
22461124 PubMed citation Europe PMC
22683823 PubMed citation Europe PMC
22967800 PubMed citation Europe PMC
22969095 PubMed citation Europe PMC
22983698 PubMed citation Europe PMC
22986894 PubMed citation Europe PMC
31478889 PubMed citation Europe PMC
33640871 PubMed citation Europe PMC
33986025 PubMed citation Europe PMC
33998365 PubMed citation Europe PMC
34018490 PubMed citation Europe PMC
34225066 PubMed citation Europe PMC
34242751 PubMed citation Europe PMC
34253597 PubMed citation Europe PMC
34299359 PubMed citation Europe PMC
34467233 PubMed citation Europe PMC
34491881 PubMed citation Europe PMC
34527569 PubMed citation Europe PMC
Last Modified
08 October 2021